SCHEMBL26078385

SCHEMBL26078385

FC(F)Oc1cccc(CC2=NCCN2)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 9/20 0.49
▸ NISCH Q9Y2I1 7/20 0.49
▸ ADRA2A P08913 5/20 0.49
▸ ADRA2B P18089 5/20 0.49
▸ ADRA2C P18825 5/20 0.49
▸ HTR1A P08908 4/20 0.49
▸ ADRA1A P35348 3/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ CYP2D6 P10635 2/20 0.49
▸ MAPT P10636 1/20 0.49
▸ OPRM1 P35372 1/20 0.49
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ HTR1D P28221 2/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ADRA1D P25100 1/20 0.42
▸ ADRA1B P35368 1/20 0.42
▸ HTR1B P28222 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26078393 0.82 TAAR1 (0.49) TAAR1NISCHADRA2AADRA2BADRA2C
SCHEMBL26078550 0.80 ADRA2C (0.43) TAAR1NISCHADRA2AADRA2BADRA2C
SCHEMBL952423 0.78 TAAR1 (0.69) TAAR1NISCHADRA2AADRA2BADRA2C
SCHEMBL953083 0.75 TAAR1 (0.68) TAAR1NISCHADRA2AADRA2BADRA2C
SCHEMBL26078386 0.74 TAAR1 (0.46) TAAR1NISCHADRA2AADRA2BADRA2C
SCHEMBL26078581 0.74 TAAR1 (0.46) TAAR1NISCHADRA2AADRA2BADRA2C
SCHEMBL954827 0.71 TAAR1 (0.68) TAAR1NISCHADRA2AADRA2BADRA2C
SCHEMBL954699 0.71 NISCH (0.53) TAAR1NISCHADRA2AADRA2BADRA2C
Hydrochloric Acid SCHEMBL9655510 0.71 NISCH (0.60) NISCHADRA2AADRA2BADRA2CHTR1A
SCHEMBL26078623 0.71 NISCH (0.58) TAAR1NISCHADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE ADRA1A, ADRB1, ADRA1D TAAR1 26/4885NISCH 1881/4885ADRA2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback